We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 1,661

Network interference - a legal guide to the commercial risks and rewards of the social media phenomenon
  • Reed Smith LLP
  • European Union, Global, United Kingdom, USA
  • April 22 2014

Social media is a revolution in the way in which corporations communicate with consumers. This White Paper will help you to maximise the huge

Supplementary protection certificates follow-up of Medeva will we go from worse to worst?
  • Hunton & Williams LLP
  • European Union, Netherlands, USA
  • November 15 2013

Yesterday, Advocate General Jääskinen gave his opinion on the questions referred by the Dutch court in the Georgetown case (C-48412

Life sciences: 2013 legal developments you need to know about
  • Mayer Brown LLP
  • China, European Union, France, USA
  • July 16 2013

This is a short guide outlining some of the key legal developments in the life sciences sector in 2013. The developments include the Supreme Court

Pharmaceutical trade marks case law round up for 2012early 2013
  • Corrs Chambers Westgarth
  • Australia, European Union, USA
  • June 6 2013

A brief wrap-up of recent decisions relating to trade marks in the pharma space from the EU, the United States and Australia

Methods of medical treatment claims issues in Canada, US and Europe
  • Gowling WLG
  • Canada, European Union, USA
  • November 30 2012

In this presentation, Scott Foster and Konrad Sechley address methods of medical treatment claims issues in Canada, US and Europe

U.S. and EU authorities focus attention on competition in pharmaceutical industry
  • Hogan Lovells
  • USA, European Union
  • March 25 2008

During the past several years, there has been an increase in antitrust enforcement directed at the pharmaceutical industry, both in the United States and in Europe, primarily focused on conduct by branded pharmaceutical companies that might affect the timing and effectiveness of entry by less costly generic drugs

The patentability of stem cells: WARF's success and failure on opposite sides of the Atlantic
  • Shepherd and Wedderburn LLP
  • European Union, United Kingdom, USA
  • March 31 2008

The Wisconsin Alumni Research Foundation (WARF) has had three of its patents in relation to stem cells (and in particular, methods of isolation) upheld by the United States Patent and Trademark Office (USPTO

Food marketing to youth discussed in Brussels
  • Shook Hardy & Bacon LLP
  • USA, European Union
  • April 8 2011

According to public health lawyer and activist Michele Simon, who recently attended a meeting in Brussels "to address the problem of cross-border marketing of unhealthy food to children," the same types of issues confronting public health advocates in the United States confront their counterparts in Europe

News bytes
  • Shook Hardy & Bacon LLP
  • European Union, USA
  • December 16 2010

The European Medicines Agency (EMA) adopts two draft guidelines as part of the regulatory approval process for certain biosimilar medicinal products

EMEA and FDA focus on clinical research safety and enforcement
  • McDermott Will & Emery
  • European Union, USA
  • August 20 2009

Recent policy changes emphasize the need for sponsoring organizations to be even more vigilant in establishing, updating and monitoring their systems for compliance with clinical research requirements, whether conducted domestically or in a foreign locale